Novel immunohistochemistry-based predictive and prognostic tests for hormone receptor-positive breast cancer

基于免疫组织化学的新型激素受体阳性乳腺癌预测和预后测试

• 批准号: 486311
• 负责人: Kaur Amandeep
• 金额: $ 1.27万
• 依托单位: University of Winnipeg
• 依托单位国家: 加拿大
• 项目类别: Studentship Programs
• 财政年份: 2022
• 资助国家: 加拿大
• 起止时间: 2022-12-01 至 2023-12-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=486311&lang=en
• 关键词: Breast Cancer; Chromatin Immuno Percipitation; Endocrine Therapy; Hormone Receptors; Immunohistochemistry; Metastatic Breast Cancer; N-Myristoylation; Nuclear Nmt Protein; Oncoproteins; Triple Negative Breast Cancer

Cancer has existed for millions of years, but even after billions of dollars in research, we haven’t found a solution that affects more than 14 million lives annually. Women account for 99% of breast cancer patients, while men account for only 1%. The lac

癌症已经存在数百万年了，但是即使经过数十亿美元的研究，我们也没有找到每年影响超过1400万生活的解决方案。女性占乳腺癌患者的99％，而男性仅占1％。鞋带